Toi, Y. et al. 2019. Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study: BSA and nintedanib reduction/discontinuation. Sarcoidosis, Vasculitis and Diffuse Lung Diseases. 36, 1 (Mar. 2019), 74–78. DOI:https://doi.org/10.36141/svdld.v36i1.7383.